Zobrazeno 1 - 10 of 18 pro vyhledávání: '"Arpana Rana"'
1
Comparative Analysis of New Drugs and Clinical Trial Rules 2019 and its impact on Approval process of Oncology Drugs
Autor: Shagun Sharma, Khushbu Sharma, Pooja Verma, Shivali Rahi, Arpana Rana
Publikováno v: International Journal of Drug Regulatory Affairs. 10:112-130
With the aim to make India as the hub for Clinical Trials and promote a transparent and faster drug approvals process for the early availability and accessibility of drugs in the country the New Drugs and Clinical Trials Rules were published on March
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e768f9b28a0dce703146d154df83c200
https://doi.org/10.22270/ijdra.v10i2.543
Zobrazit plný text záznamu
2
Oncology Drugs: Evolution, Comparative study of Global Drug Regulatory approval process and various measures to improve availability and accessibility
Autor: Shagun Sharma, Khushbu Sharma, Pooja Verma, Shivali Rahi, Arpana Rana
Publikováno v: International Journal of Drug Regulatory Affairs. 10:102-111
Cancer is the leading cause of death worldwide and is a well-known fact that it can be cured if detected and treated early. Cancer treatment has evolved from conventional therapies like vinca alkaloids, photodynamic and radiation therapy, chemotherap
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7dfe00715a5febb4915e1012b68734d6
https://doi.org/10.22270/ijdra.v10i2.542
Zobrazit plný text záznamu
4
Prodrugs- A Regulatory Prospective
Autor: Arpana Rana, Shivali Rahi
Prodrugs are unique due to special features in contrast to drugs. The primary goal of prodrug design is to conceal harmful drug features, such as low solubility in water or lipid membranes, low target selectivity, chemical instability, undesirable ta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b48b7283639235bd55d79620b141a88
Zobrazit plný text záznamu
5
Comparative study of updated Clinical Trial Regulations in India with respect to Australia, Europe, Japan and US
Autor: Arpana Rana, Shivali Rahi, Devender Kumar
Publikováno v: International Journal of Drug Regulatory Affairs. 9:48-61
The national regulatory authorities, such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), Central Drugs Standard Control Organization and the Australian Therapeutic Goods Administration (TGA), approve every drug tha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ebe583d928e7e281a7494b19e547ddd
https://doi.org/10.22270/ijdra.v9i1.455
Zobrazit plný text záznamu
7
Role of ICH guidelines in registration of Pharmaceutical Products
Autor: Shivali Rahi, Arpana Rana
Publikováno v: International Journal of Drug Regulatory Affairs. 7:14-27
The International Conference on Harmonization (ICH) of Technical Requirements is a unique project for Registration of Pharmaceutical products which are intended for human use. This brings together the regulatory authorities of Europe, Japan and Unite
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d89b5537853f667922f9d0e6c0b3067
https://doi.org/10.22270/ijdra.v7i4.365
Zobrazit plný text záznamu
8
Hand Sanitizer: Regulatory Perspective in Different Countries
Autor: Shivali Rahi, Ajay Kumar, Arpana Rana
Publikováno v: International Journal of Pharmaceutical Sciences Review and Research. 71
Considering the new Coronavirus pandemic, the interest for antimicrobial products, for example, sanitizers and hand sanitizers are soaring. Regulatory authorities are performing their function by giving approvals to hand sanitizers in various countri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e4f8e9db52578b33d7c2b94f70a68a1
https://doi.org/10.47583/ijpsrr.2021.v71i02.001
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje